(S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) 是一种从喜树中分离的 DNA 拓扑异构酶 I (DNA topoisomerase I) 抑制剂。(S)-10-Hydroxycamptothecin 可显着诱导细胞凋亡,并可用于肝癌,胃癌,结肠癌和白血病的研究。
生物活性 | (S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is aDNAtopoisomeraseIinhibitor of isolated from the Chinese plantCamptotheca accuminata. (S)-10-Hydroxycamptothecin exhibits a remarkableapoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, coloncancerand leukaemia treatment[1][2][3][4]. |
IC50& Target[1][3] | |
体外研究 (In Vitro) | (S)-10-Hydroxycamptothecin (5-20 μg/L; 6 days; Hep G2 cells) treatment results in the cell cycle arrest at G2/M phase[2]. (S)-10-Hydroxycamptothecin induces differentiation, down-regulates nuclear antigen (PCNA) and up-regulates wild-type protein p53 in Hep G2 cells[2]. (S)-10-Hydroxycamptothecin inhibits L1210 leukemia cells with an IC50of 1.15 μM[1].
Cell Cycle Analysis[2] Cell Line: | Hep G2 cells | Concentration: | 5 μg/L, 10 μg/L, 20 μg/L | Incubation Time: | 6 days | Result: | Hep G2 cells were mainly arrested at G2/M phase. |
|
体内研究 (In Vivo) | (S)-10-Hydroxycamptothecin (10-Hydroxycamptothecin) against L1210 leukemia in mice is tested. At the optimal dose (15 mg/kg), (S)-10-Hydroxycamptothecin has a 71% increase in life span (ILS)[1].
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | - Alkaloids
- Quinoline Alkaloids
- Alkaloids
- Pyrrole Alkaloids
|
来源 | - Plants
- Nyssaceae
- Camptotheca acuminataDecne.
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
溶解性数据 | In Vitro: DMSO : 50 mg/mL(137.23 mM;Need ultrasonic) 配制储备液 1 mM | 2.7446 mL | 13.7231 mL | 27.4461 mL | 5 mM | 0.5489 mL | 2.7446 mL | 5.4892 mL | 10 mM | 0.2745 mL | 1.3723 mL | 2.7446 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 2.5 mg/mL (6.86 mM); Suspended solution; Need ultrasonic
此方案可获得 2.5 mg/mL (6.86 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2.5 mg/mL (6.86 mM); Suspended solution; Need ultrasonic
此方案可获得 2.5 mg/mL (6.86 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|